A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

INTRODUCTION: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) blockade may feasibly be achieved by combining fulvestrant with anastrozole. This pre-surgical study compared fulvestrant plus anastrozole versus either agent alone in patients with ER-positive breast...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Robertson, John FR, Dixon, J Michael, Sibbering, D Mark, Jahan, Ali, Ellis, Ian O, Channon, Eddie, Hyman-Taylor, Pauline, Nicholson, Robert I, Gee, Julia MW
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672778/
https://ncbi.nlm.nih.gov/pubmed/23497452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3393
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires